- A retrospective analysis of ezetimibe treatment in renal transplant recipientsC Buchanan
University of Utah Hospitals and Clinics, Renal Transplant Program, Salt Lake City, Utah, USA
Am J Transplant 6:770-4. 2006..8% after 3.1 months of therapy. Ezetimibe as combination or monotherapy is a safe and effective treatment option for dyslipidemia in renal transplant recipients without changes in calcineurin inhibitor levels or renal function...